 |
인쇄하기
취소
|
Imbruvica & Vimizim registered for insurance benefits under special case system
A series of rare disease products that are applied by the special case system of economic evaluation will be registered for the health insurance benefit.
They are the Janssen’s mantle cell lymphoma treatment Imbruvica(ibrutinib) and Sam-Oh Pharm’s morquio A syndrome treatment Vimizim(elosulfase alfa).
The National Health Insurance Service concluded drug pricing negotiations with respective p...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.